Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Trevi Therapeutics and keeping the price target at $25.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Debanjana Chatterjee’s rating is based on several promising developments for Trevi Therapeutics. The company recently shared positive results from their Phase 2a CORAL trial, where their drug Haduvio met all secondary endpoints for treating cough in patients with idiopathic pulmonary fibrosis (IPF). This success is complemented by ongoing Phase 1 studies that are evaluating the drug’s impact on respiratory function and its interaction with standard IPF treatments, with expectations of favorable outcomes.
Furthermore, Trevi is planning to expand its clinical programs with a Phase 3 trial for IPF-related cough and a Phase 2b trial for renal cell carcinoma, both set to begin in the first half of 2026. The company is also exploring opportunities in non-IPF interstitial lung disease (ILD) cough, which could significantly broaden their market reach. With a strong cash position of $204 million, Trevi is well-funded to support these ambitious trials and initiatives, adding to the confidence in their potential for growth.
In another report released on August 8, Stifel Nicolaus also reiterated a Buy rating on the stock with a $15.00 price target.